Summary of Use during Lactation

No information is available on the clinical use of moxidectin during breastfeeding. However, amounts in breastmilk appear to be low and would not be expected to cause any adverse effects in breastfed infants. Until more data become available, moxidectin should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Drug Levels

Maternal Levels. Twelve lactating women who averaged 29.6 weeks (range 21 to 100 weeks) postpartum and had weaned their infants were given moxidectin 8 mg orally as a single dose. A breast pump was used to collect milk samples for at least 30 days, and in some, at various times for up to 90 days after the dose. The total amount of drug excreted into breastmilk averaged 0.056 mg over the study period, which was 8.7% (SD 3.2%) of the weight-adjusted maternal dose. The amount of moxidectin excreted into breastmilk tended to be higher in some women with lower maternal body weight.[1]

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.

Korth-Bradley JM, Parks V, Chalon S, et al. Excretion of moxidectin into breast milk and pharmacokinetics in healthy lactating women. Antimicrob Agents Chemother. 2011;55:5200–4. [PMC free article: PMC3195050] [PubMed: 21896908]

Substance Name

Moxidectin

CAS Registry Number

113507-06-5

Drug Class

Breast Feeding

Lactation

Anti-Infective Agents

Antiparasitic Agents

Anthelmintics

Antinematodal Agents

Insecticides

Macrolides